Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

被引:2
|
作者
Zhang, Nianping [1 ,2 ]
Guo, Peng [3 ]
Zhao, Yan [4 ]
Qiu, Xiao [2 ]
Shao, Shuai [5 ]
Liu, Zhenzhong [6 ]
Gao, Zong [7 ]
机构
[1] Shandong Univ Tradit Chinese Med, Postdoctoral Mobile Stn, Jinan 250355, Shandong, Peoples R China
[2] Shandong Univ Tradit Chinese Med, Expt Ctr, Jinan 250355, Shandong, Peoples R China
[3] Jinan Third Peoples Hosp, Dept Neurol, Jinan 250132, Shandong, Peoples R China
[4] Jinan Third Peoples Hosp, Dept Hand & Upper Limb Surg, Jinan 250132, Shandong, Peoples R China
[5] Jingmen Peoples Hosp, Dept Reprod Med, Jingmen 448000, Hubei, Peoples R China
[6] North Sichuan Med Coll, Sch Publ Hlth, Nanchong 637100, Peoples R China
[7] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Neurosurg, 16369 Jingshi Rd, Jinan 250014, Shandong, Peoples R China
关键词
Parkinson 's disease; Puerarin; Pharmacological mechanism; Dopaminergic neurons; Traditional Chinese medicine monomer; PROTECTS DOPAMINERGIC-NEURONS; UBIQUITIN-PROTEASOME SYSTEM; IN-VITRO; ISOFLAVONE PUERARIN; COUPLED RECEPTOR; OXIDATIVE STRESS; PI3K/AKT PATHWAY; O-GLCNACYLATION; MOUSE MODELS; PC12; CELLS;
D O I
10.1016/j.biopha.2024.117101
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Puerarin, a monomer of traditional Chinese medicine, is a key component of Pueraria radix . Both clinical and experimental researches demonstrated that puerarin has therapeutic effects on Parkinson 's disease (PD). Puerarin 's pharmacological mechanisms include: 1) Anti-apoptosis. Puerarin inhibits cell apoptosis through the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/protein kinase B (Akt) and c-Jun N-terminal kinase (JNK) signaling pathways. Puerarin also exerts a hormone-like effect against cell apoptosis; 2) Anti-oxidative stress injury. Puerarin inhibits the Nrf2 nuclear exclusion through the GSK-3 beta/Fyn pathway to promote the Nrf2 accumulation in the nucleus, and then promotes the antioxidant synthesis through the Nrf2/ARE signaling pathway to protect against oxidative stress; 3) Neuroprotective effects by intervening in the ubiquitinproteasome system (UPS) and autophagy-lysosomal pathway (ALP). Puerarin significantly enhances the activity of chaperone-mediated autophagy (CMA), which downregulates the expression of alpha-synuclein, reduces its accumulation, and thus improves the function of damaged neurons. Additionally, puerarin increases proteasome activity and decreases ubiquitin-binding proteins, thereby preventing toxic accumulation of intracellular proteins; 4) Alleviating inflammatory response. Puerarin inhibits the conversion of microglia to the M1 phenotype while inducing the transition of microglia to the M2 phenotype. Furthermore, puerarin promotes the secretion of anti-inflammatory factor and inhibits the expression of pro-inflammatory factors; 5) Increasing the levels of dopamine and its metabolites. Puerarin could increase the levels of dopamine, homovanillic acid (HVA) and 3,4dihydroxyphenylacetic acid (DOPAC) in the striatum; 6) Promoting neurotrophic factor expression and neuronal repair. Puerarin increases the expression of glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), thereby exerting a neuroprotective effect. Moreover, the regulation of the gut microbiota by puerarin may be a potential mechanism for the treatment of PD. The current review discusses the molecular mechanisms of puerarin, which may provide insight into the active components of traditional Chinese medicine in the treatment of PD.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease
    Sgambato-Faure, Veronique
    Cenci, Maria Angela
    PROGRESS IN NEUROBIOLOGY, 2012, 96 (01) : 69 - 86
  • [32] PUERARIN PROTECTS DOPAMINERGIC NEURONS IN PARKINSON'S DISEASE MODELS
    Zhang, X.
    Xiong, J.
    Liu, S.
    Wang, L.
    Huang, J.
    Liu, L.
    Yang, J.
    Zhang, G.
    Guo, K.
    Zhang, Z.
    Wu, P.
    Wang, D.
    Lin, Z.
    Xiong, N.
    Wang, T.
    NEUROSCIENCE, 2014, 280 : 88 - 98
  • [33] Improved pharmacological chaperones for the treatment of neuronopathic Gaucher and Parkinson's disease
    Clark, Sean
    Lee, Gary
    Boyd, Robert
    Sullivan, Sean
    Pellegrino, Lee
    Frascella, Michelle
    Khanna, Richie
    Brignol, Nastry
    Wustman, Brandon
    Rybczynski, Philip
    Benjamin, Elfrida
    Valenzano, Kenneth
    Lockhart, David J.
    MOLECULAR GENETICS AND METABOLISM, 2011, 102 (02) : S12 - S12
  • [34] Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson's Disease
    Kulick-Soper, C.
    Caspell-Garcia, C.
    Coffey, C.
    Picillo, M.
    Weintraub, D.
    Dahodwala, N.
    MOVEMENT DISORDERS, 2020, 35 : S379 - S380
  • [35] Mucuna pruriens seeds in treatment of Parkinson's disease: Pharmacological review
    Kasture S.
    Mohan M.
    Kasture V.
    Oriental Pharmacy and Experimental Medicine, 2013, 13 (3): : 165 - 174
  • [36] Study on Pharmacological Treatment of Impulse Control Disorders in Parkinson's Disease
    Furdu-Lungut, Emilia
    Antal, Claudia
    Turcu, Suzana
    Costea, Dan-Gabriel
    Mitran, Mihai
    Mitran, Loredana
    Diaconescu, Andrei-Sebastian
    Novac, Marius-Bogdan
    Gorecki, Gabriel-Petre
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (22)
  • [37] Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems
    Brichta, Lars
    Greengard, Paul
    Flajolet, Marc
    TRENDS IN NEUROSCIENCES, 2013, 36 (09) : 543 - 554
  • [38] Motor function in Parkinson's disease: from mechanisms to treatment
    Almeida, QJ
    Smiley-Oyen, AL
    Lazarus, JC
    Corcos, DM
    JOURNAL OF SPORT & EXERCISE PSYCHOLOGY, 2006, 28 : S6 - S7
  • [39] Motor fluctuations and pharmacological treatment of Parkinson's disease in Argentina. First national registry of Parkinson's disease: Parkinson en movimiento
    Peralta, C.
    Zilliani, J.
    Simonetti, D.
    Burgos, M.
    Garretto, N.
    Arakaki, T.
    Femminini, R.
    Gatto, E.
    Bauso, D.
    Chade, A.
    Fernandez Pardal, M.
    Zeppa, G.
    Giannaula, R.
    Rodriguez, M.
    Bueri, J.
    MOVEMENT DISORDERS, 2010, 25 (07) : S368 - S368
  • [40] An overview of the various medicinal plants used in the treatment of Parkinson's disease
    Shastrakar, Pranali
    Gagarani, Manish
    Mahure, Vinit
    Ukey, Bhushan
    Khobragade, Samiksha
    Vyas, Ujwal
    ANNALS OF PHYTOMEDICINE-AN INTERNATIONAL JOURNAL, 2023, 12 (02): : 41 - 46